NHS
NICE Recommends NHS England Provide AstraZeneca's Tagrisso for Adjuvant EGFR-Mutated NSCLC
The drug was previously available through the Cancer Drugs Fund, but with more data, NICE is backing routine access through the NHS.
UK's NICE Reverses Course on Immunocore's Kimmtrak for Advanced Uveal Melanoma
In recommending Kimmtrak, NICE factored in a new commercial agreement with the sponsor and changed its 2023 negative opinion.
In Brief This Week: Genomate Health, Aspira Women’s Health, U of Adelaide, Illumina, Asklepios
News items for the week of Nov. 4, 2024.
Cambridge University Hospitals Net £1.5M Grant to Develop Cell Therapy Hub in Eastern England
The funding will allow CUH to buy new equipment for administering treatments such as CAR T-cell therapies, reducing patients' need to travel long distances.
NICE Declines to Recommend Menarini's Orserdu in ESR1-Mutant Breast Cancer in England
In a draft guidance, the institute did not recommend Orserdu, but is collecting additional data and public comments on this preliminary decision.